All News
EULAR: Considerations when Transitioning from Pediatric to Adult Rheumatologic Care
EULAR has established guidance on best practices for delivering patient education in physical activity and self-management of pain during transitional care in rheumatology.
Prevalence of Autoimmune Diseases in the United States
An epidemiologic assessment of the prevalence of autoimmune diseases in the United States (US) finds that nearly 5% of the population has an autoimmune disorder, twice as many in women compared to men.
Read Article
ICYMI: VITAL Info on Autoimmune Disease (2.9.2024)
Dr. Jack Cush reviews the journal reports from the past week on RheumNow.com. Highlights are summarized by three songs: "Stairway to Heaven", "You're No Good", and "How Long (has this been going on)".
Read Article
Best of 2024: Eating for Rheumatoid Arthritis
The majority of practicing rheumatologists at RheumNow Live 2024 were unaware of the new ACR guidelines issued in 2022 regarding dietary and lifestyle recommendations for patients with Rheumatoid Arthritis. Dr. Monica Guma reviewed these guidelines during her lecture on the impact of diet on disease activity and therapeutic response.
Read Article
In #RA, Higher levels of ESR and CRP, but not DAS28, joint counts or global assessments, were significantly associated with the risk of incident ILD in RA. German biologics (RABBIT) registry study compared 139 RA-ILD vs vs 686 controls. https://t.co/Ul4HZ1hzS0 https://t.co/GLKL7U4ASt
Dr. John Cush RheumNow ( View Tweet)
Leeds study of 19 pts at-risk for RA (ACPA+ & arthralgia) finds low-diversity gut microbiome & in the 10 mos preceding the transition to RA, microbiome becomes more unstable w/ accumulation of Prevotellaceae, particularly Prevotella copri https://t.co/rbYMCl1FcO https://t.co/LWqppg36cn
Dr. John Cush RheumNow ( View Tweet)
UKs University of Birmingham researchers have just been awarded £3.5 million funding from Johnson & Johnson to investigate mechanisms of response and non-response to biologic and targeted synthetic therapies in rheumatoid arthritis. https://t.co/or9amYqljz https://t.co/EvDhVfqOig
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live 2025 kicks off in just 6 weeks! Join us Feb 8-9 in Dallas for an unmatched rheumatology event.
https://t.co/VH2ahP1XUy
Don’t miss expert insights on JAK Inhibitors from:
🔹 Madelaine Feldman, MD
🔹 Joseph F. Merola, MD
🔹 Christina Charles-Schoeman, MD… https://t.co/9dRVwLNufF https://t.co/r88g6QMBC3
Links:
Dr. John Cush RheumNow ( View Tweet)
Italian study of 458 #RA pts shows 16% (71)meeting the EULAR criteria for difficult 2 Rx RA ( D2T-RA); unrelated to age, gender, seropositivity. BUT D2T-RA was assoc w/ erosions (24% vs 11%), obesity (33% vs 19%) & FM (25% vs 10%) https://t.co/w5mliNkfBT https://t.co/m65jk62wmh
Dr. John Cush RheumNow ( View Tweet)
Zhang @jeffsparks et al. Even more evidence that MTX does not cause ILD, and in fact prevents ILD, in RA, OR 0.48 in meta-analysis. @RheumNow #ACR24 Abstr#1384 https://t.co/w5G1dEF7Vm https://t.co/cyiQqGBf01 https://t.co/r909qqIh4V
Links:
Dr. John Cush RheumNow ( View Tweet)
Seronegative RA: sometimes there's an assumption that they'll eventually get a 'real' diagnosis
at @MayoClinic, 85% of patients diagnosed with seronegative RA kept their diagnosis at 10 years.
Usually, seroneg RA means seroneg RA!
#ACR24 @MyasoedovaElena ABST0458 @RheumNow… https://t.co/lJ95hYO3vM https://t.co/zF9esDnLYh
Dr. John Cush RheumNow ( View Tweet)
Outcomes Comparison study of late-onset RA (LORA) vs younger-onset RA (YORA) showed similar Dz activity assessments over 5 years but Late onset RA had worse functional outcomes and more adverse events (adj HR 4.7 for death & 2.6 for malignancy). https://t.co/b58zJG1OuA https://t.co/WZa12O06Rf
Dr. John Cush RheumNow ( View Tweet)
A re-evaluation of lupus arthritis. Old dogma is RA is erosive and SLE non-erosive. With better imaging, lupus arthritis can be erosive. Vivianne Malstrom. @RheumNow #ACR24 https://t.co/dFRnmGMGls https://t.co/LNoCtmtVuI
Links:
Dr. John Cush RheumNow ( View Tweet)
Algorithm for the treatment of calcinosis #calcinosis @RheumNow #ACR24 https://t.co/NZhP7Enzrp https://t.co/1mO8waM5DI
Links:
Dr. John Cush RheumNow ( View Tweet)
Best of 2024: Eating for Rheumatoid Arthritis
https://t.co/gtK3F6FdEB https://t.co/ILA6lSohh7
Dr. John Cush RheumNow ( View Tweet)
Overview of Uveitis management of adult & pediatric rheumatology.
- Uveitis accounts for 10% of visual impairment globally
- TNF inhib are effective; w/ IL-6 inhib as 2nd line options https://t.co/fwhTxEpVG0 https://t.co/cKGdcDbz3d
Dr. John Cush RheumNow ( View Tweet)
Zhang @jeffsparks et al. Even more evidence that MTX does not cause ILD, and in fact prevents ILD, in RA, OR 0.48 in meta-analysis. @RheumNow #ACR24 Abstr#1384 https://t.co/w76dY29bwe https://t.co/1LBevDunjH https://t.co/Ix3UxeGUe2
Links:
Dr. John Cush RheumNow ( View Tweet)
"If you want an argument, put two rheumatologists in a room and ask them about steroid tapers. Add a third and you'll have a fight"
-P. Merkel at UPA plenary session
#ACR24 @RheumNow
Dr. John Cush RheumNow ( View Tweet)
Seronegative RA: sometimes there's an assumption that they'll eventually get a 'real' diagnosis
at @MayoClinic, 85% of patients diagnosed with seronegative RA kept their diagnosis at 10 years.
Usually, seroneg RA means seroneg RA!
#ACR24 @MyasoedovaElena ABST0458 @RheumNow… https://t.co/OD78mbDyNu https://t.co/vHgqX9IQOs
Dr. John Cush RheumNow ( View Tweet)
Should you worry about giving TNFi to RA pts after a cancer diagnosis?
Medicare data with colorectal, lung, prostate Ca:
TNFi pts survival no worse (numerically better) than csDMARDs
Cancer pts deserve good RA treatment!
#ACR24 ABST0202 Suarez-Almazor @MDAndersonNews @RheumNow… https://t.co/aR75hJQ6YK https://t.co/ptDYCsOpXN
Dr. John Cush RheumNow ( View Tweet)
